Trial Profile
Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Anastrozole; Antineoplastics; Exemestane; Letrozole; Tamoxifen
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms PACS11UNIRAD; UCBG-UNIRAD; UNIRAD
- 06 Jun 2023 Results (n=855) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 23 May 2022 Status changed from active, no longer recruiting to discontinued, according to Results published in the Journal of Clinical Oncology.
- 23 May 2022 Primary endpoint (To evaluate the benefit from adding everolimus to standard endocrine treatments after two years of treatment on the disease-free survival (DFS)) has not been met, according to Results published in the Journal of Clinical Oncology.